5 - Contents

6-7 NEWS
AbbVie to acquire Cerevel for $8.7bn; Novartis’ oral monotherapy approved by FDA for rare blood disease

8-9 NEWS
UK medicines scheme sends ‘mixed message’ to industry; Stem cell therapy shows promise in MS

10-11 DERMATOLOGY NEWS
BMS' Opdualag approved by MHRA for melanoma; Almirall and etherna partner on mRNA-based therapies

12 DARWIN'S MEDICINE
If you want change in 2024, change in 2024

13 POLICY AND PUBLIC HEALTH
March-in rights explained

14 IT'S A NEW YEAR
Taking the opportunity to start afresh

15 INNOVATIVE IMPACT BLOG
The secret of the superhuman is you (and AI)

16-17 PRECISION MEDICINE – REVOLUTIONISING TREATMENT FOR GENETIC DISEASES AND CANCER
PME talks to Joanne Kanaan from Omini about the potential role of precision medicine in chronic diseases and the challenges patients face in managing their conditions

18-19 MENTAL HEALTH – FROM RESEARCH TO REMISSION
Barriers, opportunities and the need for pioneering progress in depression

22-23 EDUCATION, AWARENESS, COLLABORATION – THE JOURNEY TO INCREASE BIOSIMILAR ADOPTION IN EUROPE
Why the future of biosimilars in Europe depends on increasing education and awareness for all

24-25 TOP PHARMA TRENDS AND PREDICTIONS FOR 2024
Looking at the role Gen AI and cutting-edge digital platforms will play in healthcare over the coming year

28-29 HEALTHCARE IN 2024 – A PRIME FOCUS ON COLLABORATION AS ORGANISATIONS FACE HUGE SOCIETAL CHALLENGES
Ed Piper, Medical & Scientific Affairs Director at AstraZeneca UK, talks to Danny Buckland about how AstraZeneca is working to improve patient outcomes

30-31 CHARTING A COURSE FOR ONGOING OMNICHANNEL EXCELLENCE
Successful customer engagement will require pharma to maintain a rigid focus throughout the journey

32-33 THE FOUR PRIORITIES SHAPING THE FUTURE OF R&D
Looking at what lies ahead for the life sciences, set against a backdrop of increasing digitalisation, climate change and emerging public health challenges

40 HEALTHCARE COMMS
OPEN Health and Nested Knowledge partner to enhance evidence synthesis with AI; Prime acquires Aventine Consulting

JANUARY 2024